Iradimed (IRMD) Common Equity (2013 - 2026)

Iradimed (IRMD) has 14 years of Common Equity data on file, last reported at $98.5 million in Q1 2026.

• On a quarterly basis, Common Equity rose 9.39% year-over-year to $98.5 million in Q1 2026; TTM through Mar 2026 was $98.5 million, a 9.39% increase from a year earlier, with the FY2025 full-year figure at $94.6 million, up 8.98% from the prior year.
• Common Equity for Q1 2026 stood at $98.5 million, up from $94.6 million in the prior quarter.
• Over the last five years, Common Equity for IRMD reached as high as $98.5 million in Q1 2026 and fell as low as $62.5 million in Q1 2022.
• Historically, Common Equity has averaged $79.6 million across 5 years, with a median of $76.1 million in 2024.
• Across the five-year window, Common Equity retreated 3.06% in 2023 and rose 21.56% in 2024, its largest moves.
• Year by year, Common Equity stood at $73.7 million in 2022, then fell by 3.06% to $71.4 million in 2023, then rose by 21.56% to $86.8 million in 2024, then gained by 8.98% to $94.6 million in 2025, then increased by 4.12% to $98.5 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $98.5 million in Q1 2026, $94.6 million in Q4 2025, and $98.4 million in Q3 2025.